Allen C. Chen

8.1k total citations · 1 hit paper
13 papers, 850 citations indexed

About

Allen C. Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Allen C. Chen has authored 13 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 2 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Allen C. Chen's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Peptidase Inhibition and Analysis (3 papers). Allen C. Chen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Peptidase Inhibition and Analysis (3 papers). Allen C. Chen collaborates with scholars based in United States, Canada and Belgium. Allen C. Chen's co-authors include Hossein Borghaei, Yun Shen, Naiyer A. Rizvi, Scott Gettinger, Laura Q.M. Chow, Christopher Harbison, Scott Antonia, Rosalyn A. Juergens, Julie R. Brahmer and Frances A. Shepherd and has published in prestigious journals such as Journal of Clinical Oncology, Urology and Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.

In The Last Decade

Allen C. Chen

13 papers receiving 825 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 350 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Allen C. Chen

Since Specialization

Citations

This map shows the geographic impact of Allen C. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allen C. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allen C. Chen more than expected).

Fields of papers citing papers by Allen C. Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allen C. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allen C. Chen. The network helps show where Allen C. Chen may publish in the future.

Co-authorship network of co-authors of Allen C. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Allen C. Chen. A scholar is included among the top collaborators of Allen C. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allen C. Chen. Allen C. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Specificity of ABCA7-mediated cell lipid efflux 2022 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Antonino Picataggi, Amrith Rodrigues, Debra Cromley, Hu Wang, (unknown), (unknown), Jeffrey T. Billheimer, (unknown), Jessica A. Hurt, Allen C. Chen, Xianlin Han, Daniel J. Rader, Domenico Praticò, Nicholas N. Lyssenko	11
2	Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Naiyer A. Rizvi, Matthew D. Hellmann, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei, Scott Gettinger, Laura Q.M. Chow, David E. Gerber, Scott A. Laurie, Jonathan W. Goldman, Frances A. Shepherd, Allen C. Chen, Yun Shen, Faith E. Nathan, Christopher Harbison, Scott Antonia	350
3	Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. 2014 ·Journal of Clinical Oncology ·Scott Antonia, Scott Gettinger, Laura Q.M. Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Allen C. Chen, Neal Ready, Naiyer A. Rizvi	118
4	Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. 2014 ·Journal of Clinical Oncology ·Naiyer A. Rizvi, Laura Q.M. Chow, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Scott Gettinger	99
5	A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). 2014 ·Journal of Clinical Oncology ·David P. Carbone, Mark A. Socinski, Allen C. Chen, Prabhu Bhagavatheeswaran, Martin Reck, Luis Paz‐Ares	12
6	First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. 2014 ·Journal of Clinical Oncology ·Scott Gettinger, Frances A. Shepherd, Scott Antonia, Julie R. Brahmer, Laura Q.M. Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Naiyer A. Rizvi	87
7	Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). 2014 ·Journal of Clinical Oncology ·Scott Antonia, Julie R. Brahmer, Scott Gettinger, Laura Q.M. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, David E. Gerber, Jonathan W. Goldman, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Hossein Borghaei, Naiyer A. Rizvi	72
8	A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). 2013 ·Journal of Clinical Oncology ·Naiyer A. Rizvi, Scott Antonia, Laura Q.M. Chow, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei, Frances A. Shepherd, Scott A. Laurie, David E. Gerber, Jonathan W. Goldman, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Scott Gettinger	39
9	An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL). 2013 ·Journal of Clinical Oncology ·F. Stephen Hodi, Christine Baudelet, Allen C. Chen, Jeffrey S. Weber	5
10	A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). 2012 ·Journal of Clinical Oncology ·Eugene Paschold, Julien Mazières, H. Léna, Giorgio Cruciani, Glen Laird, Ian Walters, Allen C. Chen, Ovidiu C. Trifan	2
11	Complications of androgen-deprivation therapy in men with prostate cancer 2005 ·Current Urology Reports ·Allen C. Chen, Daniel P. Petrylak	21
12	Prostate-specific antigen, sex steroid hormones, and the insulin-like growth factor axis in U.S.-born, Jamaican, and Haitian black men: A pilot study 2004 ·Urology ·Allen C. Chen, Richard J. Macchia, Francine Conway, Carol Magai, Manisha Desai, Alfred I. Neugut	5
13	Complications of androgen deprivation therapy in men with prostate cancer 2004 ·Current Oncology Reports ·Allen C. Chen, Daniel P. Petrylak	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact